We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
- Authors
Mao, Yue-ying; Cai, Hua-cong; Shen, Kai-ni; Chang, Long; Zhang, Lu; Zhang, Yan; Feng, Jun; Wang, Wei; Yang, Chen; Zhu, Tie-nan; Duan, Ming-hui; Zhou, Dao-bin; Cao, Xin-xin; Li, Jian
- Abstract
Idarubicin 12 mg/m2 has been recommended as a standard induction therapy for acute myeloid leukemia (AML). It is unknown whether a higher dose of idarubicin can improve the remission rate. This phase 2 prospective single-arm study enrolled 45 adults with newly diagnosed AML between September 2019 and May 2021 (NCT 04,069,208). Induction therapy included administration of idarubicin 14 mg/m2 for 3 days and cytarabine 100 mg/m2 every 12 h subcutaneously for 7 days. The primary endpoint was the composite complete response rate (complete response (CR) plus complete response with incomplete blood count recovery (CRi)). The median age was 45 years (range 14–60 years). Forty (88.9%) patients had CR or CRi, including 39 patients with CR and 1 patient with CRi after one course of induction therapy. The median times to recovery of absolute neutrophil and platelet counts were 21 days. Only 1 patient died of intracranial hemorrhage during induction therapy. After a median follow-up of 14 months (range 3.5–24 months), the estimated 18-month overall survival and disease-free survival (DFS) were 66.9% and 57.5%, respectively. In conclusion, idarubicin 14 mg/m2 plus cytarabine was a safe and efficient intensive regimen for younger and fit patients with newly diagnosed AML.
- Subjects
ACUTE myeloid leukemia; IDARUBICIN; PROGRESSION-free survival; INTRACRANIAL hemorrhage; PLATELET count
- Publication
Annals of Hematology, 2022, Vol 101, Issue 4, p831
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-022-04764-4